IVIG Therapy in Common Variable Immunodeficiency

Primary Justification

The American Academy of Allergy, Asthma, and Immunology recommends that immunoglobulin replacement therapy should be continued lifelong for patients with primary immunodeficiency disorders, such as common variable immunodeficiency (CVID), regardless of achieving target IgG levels 1
The development of bronchiectasis in CVID patients strengthens the indication for continued immunoglobulin replacement therapy (IGRT), as it represents irreversible organ damage that occurred despite treatment, and early diagnosis and continuous therapy are critical to prevent progression of bronchiectasis and additional permanent lung damage 1
The effectiveness of polyclonal human IgG for reducing serious bacterial infections in CVID patients is well-established, with long-term administration resulting in substantial reduction of pneumonic episodes 1
The recent H. influenzae bacterial bronchitis episode in a CVID patient, despite "normal" IgG levels, is clinical evidence that the current dosing may be inadequate for the patient's disease burden 2

IgG trough levels must be monitored at least every 6-12 months, with more frequent monitoring (every 2 weeks initially) if dose adjustments are made, and the target trough level should be individualized based on clinical response, not just laboratory values 1
Complete blood counts and serum chemistry should be monitored regularly to detect potential adverse effects including hemolysis, renal dysfunction, and hyperproteinemia 1
The primary endpoint is clinical response—specifically reduction in infection frequency and severity—not simply achieving a numerical IgG target, although this patient's recent bacterial bronchitis suggests the need for continued vigilance and possible dose optimization 1

This patient meets all criteria for continuation of IGRT: documented primary immunodeficiency disorder (CVID), IgG trough levels being monitored at least yearly, and clinical evidence of ongoing infection risk despite therapy 1
Maintaining IgG levels "at or above the lower range of normal for age" is a minimum standard, not an optimal target for patients with established complications like bronchiectasis 1

The goal of IGRT is prevention of infections and further organ damage, not reactive treatment after damage has occurred, and dose adjustments should not be delayed while waiting for recurrent infections to establish a pattern 1

The American Academy of Allergy, Asthma, and Immunology recommends immunoglobulin replacement therapy for patients with Common Variable Immunodeficiency (CVID) who have low serum IgG levels and poor specific antibody responses to pneumococcal vaccination, as seen in this patient 3, 4
Patients with CVID typically have abnormal B-cell counts and impaired humoral immunity, consistent with the diagnosis in this case 4, 5
The patient's history of multiple infections, including pneumonia, recurrent sinus infections, and cellulitis, meets the criteria for immunoglobulin replacement therapy 3, 6

The American Academy of Allergy, Asthma, and Immunology guidelines suggest that IVIG therapy can significantly reduce the frequency and severity of infections in CVID patients, as demonstrated by the patient's improvement since starting treatment 3
Regular monitoring of IgG trough levels is essential to ensure adequate replacement therapy, with target levels between 8-11 g/L, as seen in this patient 3

The standard dosing guidelines for CVID recommend IVIG administration every 28 days, with a dose of approximately 0.5g/kg, which is consistent with the patient's treatment regimen 3
Patients on IVIG therapy should have regular monitoring of blood counts and serum chemistry to detect potential adverse effects, as recommended by the American Academy of Allergy, Asthma, and Immunology 3, 7